Log in

Relevant bibliographies by topics / Breast Metastasis. Plasminogen. Urokinase

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Breast Metastasis. Plasminogen. Urokinase'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast Metastasis. Plasminogen. Urokinase.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast Metastasis. Plasminogen. Urokinase"

1

Smaradhania, Nilam, Septiman Rahman, Salman Ardi Syamsu, and Prihantono Prihantono. "Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer." Breast Disease 40 (June 25, 2021): S1—S7. http://dx.doi.org/10.3233/bd-219001.

Full text

Abstract:

BACKGROUND: The plasminogen urokinase activation system consists of urokinase plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor type 1 (PAI-1), which are considered to have a relationship with cancer aggressiveness. Several studies have found correlations between HER2 mRNA and uPAR in disseminated tumor cells (DTCs) in breast cancer patients. They are associated with a more aggressive primary tumor phenotype and recurrence/metastasis. OBJECTIVE: This study aims to determine the relationship between the expression of urokinase-type plasminogen activator recepto

APA, Harvard, Vancouver, ISO, and other styles

2

Tang, Linlin, and Xiuzhen Han. "The urokinase plasminogen activator system in breast cancer invasion and metastasis." Biomedicine & Pharmacotherapy 67, no. 2 (2013): 179–82. http://dx.doi.org/10.1016/j.biopha.2012.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Maguire, T. M., S. G. Shering, C. M. Duggan, E. W. McDermott, N. J. O'Higgins, and M. J. Duffy. "High Levels of Cathepsin B Predict Poor Outcome in Patients with Breast Cancer." International Journal of Biological Markers 13, no. 3 (1998): 139–44. http://dx.doi.org/10.1177/172460089801300303.

Full text

Abstract:

Cathepsin B (CB) is a thiol-stimulated protease implicated in cancer invasion and metastasis. Other proteases involved in cancer spread such as urokinase-type plasminogen activator (uPA) and cathepsin D have previously been shown to be prognostic markers in breast cancer. CB was assayed by ELISA in 193 patients with primary breast cancer. CB levels were significantly higher in both primary and metastatic breast tumors than in fibroadenomas (p=0.0001). In the primary carcinomas, CB levels showed no significant correlation with either nodal status, tumor size or estrogen receptor (ER) status. Pa

APA, Harvard, Vancouver, ISO, and other styles

4

Clarke, Christopher J., Stephane R. Gross, Thamir M. Ismail, et al. "Activation of tissue plasminogen activator by metastasis-inducing S100P protein." Biochemical Journal 474, no. 19 (2017): 3227–40. http://dx.doi.org/10.1042/bcj20170578.

Full text

Abstract:

S100P protein in human breast cancer cells is associated with reduced patient survival and, in a model system of metastasis, it confers a metastatic phenotype upon benign mammary tumour cells. S100P protein possesses a C-terminal lysine residue. Using a multiwell in vitro assay, S100P is now shown for the first time to exhibit a strong, C-terminal lysine-dependent activation of tissue plasminogen activator (tPA), but not of urokinase-catalysed plasminogen activation. The presence of 10 μM calcium ions stimulates tPA activation of plasminogen 2-fold in an S100P-dependent manner. S100P physicall

APA, Harvard, Vancouver, ISO, and other styles

5

Duffy, Michael J. "Urokinase Plasminogen Activator and Its Inhibitor, PAI-1, as Prognostic Markers in Breast Cancer: From Pilot to Level 1 Evidence Studies." Clinical Chemistry 48, no. 8 (2002): 1194–97. http://dx.doi.org/10.1093/clinchem/48.8.1194.

Full text

Abstract:

Abstract Background: For optimum management of patients with cancer, accurate assessment of prognosis is essential. The primary determinant of outcome in malignancy is the formation of distant metastases. Urokinase plasminogen activator (uPA) is a serine protease causally involved in invasion and metastasis. Content: Data from model systems show that uPA is unequivocally involved in cancer dissemination. Consistent with its role in metastasis, multiple independent groups have shown that high uPA concentrations in primary breast cancers correlate with poor prognosis. For determining outcome, th

APA, Harvard, Vancouver, ISO, and other styles

6

Duffy, M. J. "Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers." Biochemical Society Transactions 30, no. 2 (2002): 207–10. http://dx.doi.org/10.1042/bst0300207.

Full text

Abstract:

Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis. Multiple studies have shown that breast cancer patients whose primary cancer contains high levels of uPA have a significantly worse outcome than patients with low levels. As a prognostic marker for breast cancer the information supplied by uPA is both independent of traditionally used factors and significant in the important subgroup of axillary-node patients. Paradoxically, high levels of plasminogen activator inhibitor-1 (PAI-1), an endogenous i

APA, Harvard, Vancouver, ISO, and other styles

7

Belfiore, Lisa, Darren N. Saunders, Marie Ranson, and Kara L. Vine. "N-Alkylisatin-Loaded Liposomes Target the Urokinase Plasminogen Activator System in Breast Cancer." Pharmaceutics 12, no. 7 (2020): 641. http://dx.doi.org/10.3390/pharmaceutics12070641.

Full text

Abstract:

The urokinase plasminogen activator and its receptor (uPA/uPAR) are biomarkers for metastasis, especially in triple-negative breast cancer. We prepared anti-mitotic N-alkylisatin (N-AI)-loaded liposomes functionalized with the uPA/uPAR targeting ligand, plasminogen activator inhibitor type 2 (PAI-2/SerpinB2), and assessed liposome uptake in vitro and in vivo. Receptor-dependent uptake of PAI-2-functionalized liposomes was significantly higher in the uPA/uPAR overexpressing MDA-MB-231 breast cancer cell line relative to the low uPAR/uPAR expressing MCF-7 breast cancer cell line. Furthermore, N-

APA, Harvard, Vancouver, ISO, and other styles

8

Duffy, Michael J., Catherine Duggan, Hugh E. Mulcahy, Enda W. McDermott, and Niall J. O’Higgins. "Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease." Clinical Chemistry 44, no. 6 (1998): 1177–83. http://dx.doi.org/10.1093/clinchem/44.6.1177.

Full text

Abstract:

Abstract Urokinase plasminogen activator (uPA) is a serine protease causally involved in cancer invasion and metastasis. In this study, high concentrations of uPA in primary breast cancers were independently associated with both a shortened disease-free interval and overall survival. For the disease-free interval as endpoint, uPA was a stronger indicator of outcome than lymph node status, whereas for overall survival, nodal status was stronger than uPA. In patients without metastasis to axillary nodes, uPA was also an independent prognostic marker, using both the disease-free interval and over

APA, Harvard, Vancouver, ISO, and other styles

9

Turner, David P., Victoria J. Findlay, A. Darby Kirven, Omar Moussa, and Dennis K. Watson. "Global Gene Expression Analysis Identifies PDEF Transcriptional Networks Regulating Cell Migration during Cancer Progression." Molecular Biology of the Cell 19, no. 9 (2008): 3745–57. http://dx.doi.org/10.1091/mbc.e08-02-0154.

Full text

Abstract:

Prostate derived ETS factor (PDEF) is an ETS (epithelial-specific E26 transforming sequence) family member that has been identified as a potential tumor suppressor. In multiple invasive breast cancer cells, PDEF expression inhibits cell migration by preventing the acquisition of directional morphological polarity conferred by changes in cytoskeleton organization. In this study, microarray analysis was used to identify >200 human genes that displayed a common differential expression pattern in three invasive breast cancer cell lines after expression of exogenous PDEF protein. Gene ontology a

APA, Harvard, Vancouver, ISO, and other styles

10

Miles, Lindsey A., Nagyung Baik, Stan Krajewski, Robert J. Parmer, and Barbara M. Mueller. "The Novel Plasminogen Receptor, Plg-RKT, and Breast Cancer Progression." Blood 118, no. 21 (2011): 853. http://dx.doi.org/10.1182/blood.v118.21.853.853.

Full text

Abstract:

Abstract Abstract 853 The ability of tumor cells to bind plasminogen is highly correlated with their invasive and metastatic potential. Here we evaluate cell surface plasminogen binding in human breast cancer. In a xenograft model for aggressive, triple-negative human breast cancer, tumor cells harvested from orthotopic mammary fat pad (mfp) tumors of the invasive human breast cancer line, MDA-MB-231, exhibit dramatic increases in tumor growth and lung and lymph node metastases, compared to parental cells. The breast cancer cells isolated from the mfp have been designated as 231mfp cells. Alth

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Breast Metastasis. Plasminogen. Urokinase"

1

Stillfried, Gillian Erika. "Urokinase-dependent plasminogen binding and activation on breast cancer cells an important process linked to malignancy /." Access electronically, 2007. http://ro.uow.edu.au/theses/13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shikimi, Keisuke. "Role of methyl CpG binding protein 2 in regulation of urokinase plasminogen activator espression and breast cancer metastasis." Thesis, McGill University, 2006. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=101796.

Full text

Abstract:

Invasion and metastasis are crucial steps in breast cancer for patient's survival. Recent studies suggest the involvement of loss of DNA methylation resulting in the activation of prometastatic genes, such as uPA and heparanase, during metastasis progression. Also, global DNA hypomethylation and regional DNA hypermethylation are associated with tumorigenesis. Methylated CpG binding protein 2 (MBD2) binds to methylated DNA and demethylates it. Early growth response 1 (EGR1) is also implicated in metastasis and DNA demethylation. We show in this study that MBD2 expression in breast cancer cell l

APA, Harvard, Vancouver, ISO, and other styles

3

Hewin, David Fitzgerald. "An investigation of the plasminogen activator system in human oesophageal and gastric carcinoma." Thesis, University of Bristol, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Billström, Anita. "The significance of urokinase-type plasminogen activator (u-PA) in tumour growth and linomide-induced upregulation of u-PA's endogenous inhibitor PAI-2." Lund : Research Laboratory, Dept. of Obstetrics and Gynaecology, Lund University Hospital, 1997. http://catalog.hathitrust.org/api/volumes/oclc/39751812.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Qazi, Romena. "The role of the urokinase family in invasion by breast cancer." Thesis, University of Glasgow, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.266538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sloan, Stakleff Kimberly Denise. "CHARACTERIZATION OF UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) AND INTEGRIN SUBUNITS IN BREAST CARCINOMA CELL LINES WITH DIVERSE INVASIVE CAPACITIES." Kent State University / OhioLINK, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=kent1195663733.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kendziora, Elena Stephanie [Verfasser], Viktor [Akademischer Betreuer] Magdolen, Wilko [Gutachter] Weichert, and Viktor [Gutachter] Magdolen. "Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC) / Elena Stephanie Kendziora ; Gutachter: Wilko Weichert, Viktor Magdolen ; Betreuer: Viktor Magdolen." München : Universitätsbibliothek der TU München, 2020. http://d-nb.info/1208325000/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Moquet-Torcy, Gabriel. "Mécanismes transcriptionnels gouvernés par Fra-1 et Fra-2 dans les cancers du sein agressifs." Thesis, Montpellier 2, 2011. http://www.theses.fr/2011MON20244/document.

Full text

Abstract:

Le cancer du sein est la principale cause de mortalité par cancer chez la femme. Deux des facteurs de transcription de la famille Fos, Fra-1 et Fra-2, sont surexprimés dans les cancers du sein agressifs et contribuent au phénotype tumoral en favorisant entre autres, la prolifération, la motilité et l'invasivité. De façon surprenante, les mécanismes moléculaires via lesquels Fra-1 et Fra-2 (et plus généralement le complexe transcriptionnel AP-1 dont ils sont des constituants) gouvernent la transcription de leurs gènes cibles sont quasi-inconnus. Dans ce contexte, en combinant diverses approches

APA, Harvard, Vancouver, ISO, and other styles

9

Biermann, Julia [Verfasser]. "Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue / Julia Christina Biermann." 2009. http://d-nb.info/999935976/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cheng, Fang-Ju, and 鄭方茹. "Effect of docosahexaenoic acid on EGF-induced urokinase plasminogen activator and matrix metalloproteinase-1/-9 expression in SK-BR3 human breast cancer cells." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/19469502735580997495.

Full text

Abstract:

碩士<br>中山醫學大學<br>營養學研究所<br>101<br>Breast cancer is the most commonly diagnosed cancer among women all over the world. Metastasis is the leading cause of death from breast cancer. EGFR and ErbB2 are an important oncogene overexpressed in about 20~30% of breast cancers, and was associated with poor patient outcome and distant metastasis. Previous study showed the induction of urokinase plasminogen activator (uPA) and matrix metalloproteinase (MMP)-1 and MMP-9 activity and expression were associated with breast cancer metastasis. EGF up-regulated uPA, MMP-1, MMP-9 expression by activating EGFR/Erb

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Breast Metastasis. Plasminogen. Urokinase"

1

Pedersen, Anders N., Claus Holst-Hansen, Thomas L. Frandsen, Boye Schnack Nielsen, Ross W. Stephens, and Nils Brünner. "The Urokinase Plasminogen Activation System in Breast Cancer." In Breast Cancer. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-456-6_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Duffy, Michael J. "Urokinase-Type Plasminogen Activator and PAI-1." In Biomarkers in Breast Cancer. Humana Press, 2006. http://dx.doi.org/10.1385/1-59259-915-x:111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Stephens, Ross W., Nils Brünner, Fritz Jänicke, and Manfred Schmitt. "The urokinase plasminogen activator system as a target for prognostic studies in breast cancer." In Prognostic variables in node-negative and node-positive breast cancer. Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5195-9_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Magdolen, Viktor, Achim Krüger, Sumito Sato, et al. "Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells in Vitro and in Vivo." In Molecular Staging of Cancer. Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-59349-9_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Brünner, Nils, Charles Pyke, Claus Holst Hansen, John Rømer, Jan Grøndahl-Hansen, and Keld Danø. "Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): Regulators of proteolysis during cancer invasion and prognostic parameters in Breast cancer." In Cancer Treatment and Research. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2592-9_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tyndall, Joel D. A., Michael J. Kelso, and Marie Ranson. "Inhibitors of the Plasminogen Activation System - Promising New Agents for Suppressing Breast Cancer Metastasis." In Frontiers in Anti-Cancer Drug Discovery. BENTHAM SCIENCE PUBLISHERS, 2011. http://dx.doi.org/10.2174/978160805161811001010055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast Metastasis. Plasminogen. Urokinase"

1

Artmann, A., K. Celik, M. Kiechle, EJ Rummeny, M. Schmitt, and N. Harbeck. "Concentrations of plasminogen activator inhibitor type1 (PAI-I) and urokinase-type plasminogen aktivator (uPA) in primary breast cancer (BC) tissue and corresponding axillary lymph node metastasis." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Banys-Paluchowski, M., T. Fehm, I. Witzel, et al. "The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer." In Abstracts of the 10th Scientific Symposium of the Comission for Translational Research of the Working group for Gynecologic Oncology AGO e.V. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1675453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ides, Johan, Christel Vangestel, Jonas Messagie, et al. "Abstract 3910: Targeting urokinase plasminogen activator: evaluation of activity-based imaging probes in an orthotopic breast cancer model." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3910.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Reedijk, MJ, M. Shimizu, B. Cohen, P. Goldvasser, H. Berman, and C. Virtanen. "Abstract P4-06-12: The Urokinase-Type Plasminogen Activator Is a Direct JAG1- Mediated Notch Target in Breast Cancer." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p4-06-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Singer, CF, M. Filipits, S. Jahn, et al. "Abstract P2-08-21: Stromal co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p2-08-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Laug, Walter E. "HETEROGENOUS EXPRESSION OF PLASMINOGEN ACTIVATOR (PA) GENES IN THE HUMAN SARCOMA CELL LINE HT1080." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644395.

Full text

Abstract:

Tumor cell derived PA activities are of crucial importance for tissue invasion and destruction by tumor cells. Therefore, we studied the expression of the PA genes in HT1080 cells using immunoenzymatic methods and specific PA gene probes.Immunenzymatic methods allowed only for the detection of urokinase like PA (u-PA) activities in HT1080 cells which was suppressed by treatment of the cells with dexamethasone (10-7 m). Despite the lack of u-PA activities, the cells still degraded extracellular tissue glycoproteins. Northern blot analysis with specific PA gene probe showed that HT1080 cells exp

APA, Harvard, Vancouver, ISO, and other styles

7

Kruithof, E. KO, W. D. Schleuning, and F. Bachman. "PLASMINOGEN ACTIVATOR INHIBITOR BIOCHEMICAL AND CLINICAL ASPECTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644764.

Full text

Abstract:

Plasminogen activator (PAs) are enzymes that convert the zymogen plasminogen into the trypsin-like protease plasmin, which degrades extracellular matrix proteins and fibrin in the course of fibrinolysis, embryogenesis, tissue remodeling and in tumor metastasis. Plasminogen activator inhibitors (PAIs) are important modulators of PA activity. Several proteins have been identified which inhibit at fast rates urokinase (u-PA) and tissue-type PA (t-PA). In the order of inhibition rate constants these are: a) PAI-1, present in human plasma and platelet extracts and purified from human endothelial ce

APA, Harvard, Vancouver, ISO, and other styles

8

Sehrawat, Anuradha, Su-Hyeong Kim, and Shivendra V. Singh. "Abstract 565: Benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells is associated with downregulation of urokinase-type plasminogen activator and its receptor." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Arnoux, D., B. Boutière, N. Pourreau-Schneider, P. Martin, and J. Sampol. "PLASMINOGEN ACTIVATORS (t-PA and u-PA) IN HUMAN NEOPLASTIC CELL LINES AND THEIR MODULATION BY BASEMENT MEMBRANE COMPONENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643190.

Full text

Abstract:

Plasminogen activators (PA)may play an important role in the regulation of enzyme activation relative to basement membrane degradation associated with the invasive growth of tumors. In order to acquire a better understanding of the complex cascade reactions leading to the formation of plasmin, we have undertaken a comparative study of urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators in cellular extracts of 20 human cancer cell lines (13 malignant melanomas, 6 breast adenocarcinomas and 1 vulvar carcinoma). Four malignant cell lines,showing various t-PA or u-PA activity level

APA, Harvard, Vancouver, ISO, and other styles

10

Mudiyanselage, Chandana S. K. Herath, Abhinit Shah, Neil Mitra, et al. "Abstract 3937: Minimally invasive colorectal resection (MICR) is associated with elevated plasma levels of Urokinase-type Plasminogen Activator-1 (uPA) from 2ndto 6thweek after surgery which may promote tumor growth and metastasis." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3937.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!